Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update.
Hansoh Pharmaceutical Group Company Limited announced that its innovative drug XINYUE (Inebilizumab Injection) received approval from the National Medical Products Administration of China for a second indication, targeting immunoglobulin G4-related disease in adults. This approval, which follows a priority review, enhances the company’s product offerings and strengthens its position in the pharmaceutical market, potentially benefiting stakeholders by expanding treatment options for patients.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company operates primarily in the Chinese Mainland, Hong Kong, and Macau markets, with a strong emphasis on targeting diseases such as neuromyelitis optica spectrum disorder and immunoglobulin G4-related disease.
Average Trading Volume: 12,157,377
Technical Sentiment Signal: Buy
Current Market Cap: HK$218.1B
For detailed information about 3692 stock, go to TipRanks’ Stock Analysis page.